LegalMay 1, 2026, 04:15 PM
Context Therapeutics Resolves Lawsuit, $850K Fee Paid by Third Party
AI Summary
Context Therapeutics Inc. announced the resolution of a stockholder class action lawsuit. The Delaware Court approved a stipulation deeming certain charter provisions, including 3-year director terms and removal only for cause, invalid and unenforceable. The Company filed a Certificate of Correction to reflect these changes. A third-party service provider agreed to pay the $850,000 mootness fee to plaintiff's counsel, which was paid on May 1, 2026, leading to the dismissal of the action. The case will officially close after the 2026 annual meeting quorum is confirmed.
Key Highlights
- Delaware Court approved stipulation on stockholder class action filed February 4, 2026.
- Company's charter provisions for 3-year director terms and removal for cause deemed invalid.
- Company filed Certificate of Correction reflecting invalid and unenforceable provisions.
- Action dismissed with prejudice, court retained jurisdiction for mootness fee application.
- Third-party service provider agreed to pay the mootness fee in full on behalf of the Company.
- Court granted Stipulated Order requiring $850,000 in fees and expenses to plaintiff's counsel.
- Provider paid the $850,000 mootness fee in full on May 1, 2026.
- Action will close after quorum is achieved at the Company's 2026 annual meeting on June 24, 2026.
Price Impact
More from CNTX